Cost effectiveness of the sirolimus-eluting stent in high-risk patients in Canada: An analysis from the C-SIRIUS trial

American Journal of Cardiovascular Drugs

Volumn 6, Issue 3, 2006, Pages 159-168

  Rinfret, Stéphane ^a,e   Cohen, David J ^a   Tahami Monfared, Amir A ^a   LeLorier, Jacques ^b   Mireault, Jean ^c   Schampaert, Erick ^d  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b HARVARD CLINICAL RESEARCH INSTITUTE   (United States)

^c INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

^d HÔPITAL DU SACRÉ COEUR DE MONTRÉAL   (Canada)

^e NOTRE DAME HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; EPTIFIBATIDE; RAPAMYCIN;

ADULT; ARTICLE; CANADA; CLINICAL PRACTICE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; COST EFFECTIVENESS ANALYSIS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG ELUTING STENT; DRUG SAFETY; DRUG UTILIZATION; ECONOMIC ASPECT; EMERGENCY WARD; FEMALE; FOLLOW UP; HEALTH CARE COST; HEART CATHETERIZATION; HEART INFARCTION; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; MALE; MEDICAL FEE; MEDICAL SOCIETY; OUTPATIENT; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVASCULARIZATION; SENSITIVITY ANALYSIS;

ADULT; AGED; ANGIOPLASTY, BALLOON, CORONARY; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CANADA; CORONARY RESTENOSIS; CORONARY STENOSIS; COST-BENEFIT ANALYSIS; FEMALE; FOLLOW-UP STUDIES; HEALTH RESOURCES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REOPERATION; RISK FACTORS; SENSITIVITY AND SPECIFICITY; SIROLIMUS; STENTS; TREATMENT OUTCOME;

EID: 33745503639     PISSN: 11753277     EISSN: 11753277     Source Type: Journal    
DOI: 10.2165/00129784-200606030-00003     Document Type: Article

References (33)

1. Parisi AF, Folland ED, Hartigan P. A comparison of angioplasty with medical therapy in the treatment of single-vessel coronary artery disease. Veterans Affairs ACME Investigators. N Engl J Med 1992; 326 (1): 10-6
2. RITA-2 trial participants. Coronary angioplasty versus medical therapy for angina: the second Randomised Intervention Treatment of Angina (RITA-2) trial. Lancet 1997; 350 (9076): 461-8
3. Pocock SJ, Henderson RA, Clayton T, et al. Quality of life after coronary angioplasty or continued medical treatment for angina: three-year follow-up in the RITA-2 trial. Randomized Intervention Treatment of Angina. J Am Coll Cardiol 2000; 35 (4): 907-14
4. Williams DO, Holubkov R, Yeh W, et al. Percutaneous coronary intervention in the current era compared with 1985-1986: the National Heart, Lung, and Blood Institute registries. Circulation 2000; 102 (24): 2945-51
5. Weintraub WS, Ghazzal ZM, Douglas JS, et al. Long-term clinical follow-up in patients with angiographic restudy after successful angioplasty. Circulation 1993; 87 (3): 831-40
6. Rinfret S, Grines CL, Cosgrove RS, et al. Quality of life after balloon angioplasty or stenting for acute myocardial infarction: one-year results from the Stent-PAMI trial. J Am Coll Cardiol 2001; 38 (6): 1614-21
7. Cohen DJ, Taira DA, Berezin R, et al. Cost-effectiveness of coronary stenting in acute myocardial infarction: results from the stent primary angioplasty in myocardial infarction (stent-PAMI) trial. Circulation 2001; 104 (25): 3039-45
8. Cohen DJ, Bakhai A, Shi C, et al. Cost-effectiveness of sirolimus-eluting stents for treatment of complex coronary stenoses: results from the Sirolimus-Eluting Balloon Expandable Stent in the Treatment of Patients With De Novo Native Coronary Artery Lesions (SIRIUS) trial. Circulation 2004; 110 (5): 508-14
9. de Feyter PJ, Kay P, Disco C, et al. Reference chart derived from post-stent-implantation intravascular ultrasound predictors of 6-month expected restenosis on quantitative coronary angiography. Circulation 1999; 100 (17): 1777-83
10. Sousa JE, Serruys PW, Costa MA. New frontiers in cardiology: drug-eluting stents: Part I. Circulation 2003; 107 (17): 2274-9
11. Sousa JE, Serruys PW, Costa MA. New frontiers in cardiology: drug-eluting stents: Part II. Circulation 2003; 107 (18): 2383-9
12. Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003; 349 (14): 1315-23
13. Stone GW, Ellis SG, Cox DA, et al. One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial. Circula-tion 2004; 109 (16): 1942-7
14. Schampaert E, Cohen EA, Schluter M, et al. The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS). J Am Coll Cardiol 2004; 43 (6): 1110-5
15. Babapulle MN, Joseph L, Belisle P, et al. A hierarchical Bayesian meta-analysis of randomised clinical trials of drug-eluting stents. Lancet 2004; 364 (9434): 583-91
16. Cutlip DE, Chhabra AG, Baim DS, et al. Beyond restenosis: five-year clinical outcomes from second-generation coronary stent trials. Circulation 2004; 110 (10): 1226-30
17. Serruys PW, van Hout B, Bonnier H, et al. Randomised comparison of implanta-tion of heparin-coated stents with balloon angioplasty in selected patients with coronary artery disease (BENESTENT II) [published erratum appears in Lancet 1998 Oct 31; 352 (9138): 1478]. Lancet 1998; 352 (9129): 673-81
18. Brophy JM, Belisle P, Joseph L. Evidence for use of coronary stents: a hierarchical bayesian meta-analysis. Ann Intern Med 2003; 138 (10): 777-86
19. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. The EPISTENT Investigators: Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. Lancet 1998; 352 (9122): 87-92
20. Rankin JM, Spinelli JJ, Carere RG, et al. Improved clinical outcome after wide-spread use of coronary-artery stenting in Canada. N Engl J Med 1999; 341 (26): 1957-65
21. Shrive FM, Manns BJ, Galbraith PD, et al. Economic evaluation of sirolimus-eluting stents. CMAJ 2005; 172 (3): 345-51
22. Brophy J, Erickson L. Agence d'Évaluation des Technologies et des Modes d'Intervention en Santé (AETMIS). An economic analysis of drug eluting coronary stents: a Québec perspective (AETMIS 04-04). Montréal: AETMIS, 2004
23. Mittmann N, Brown A, Seung SJ, et al. Economic evaluation of drug eluting stents [technology report no. 53]. Ottawa: Canadian Coordinating Office for Health Technology Assessment, 2005
24. Steinhubl SR, Berger PB, Mann JT, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002; 288 (19): 2411-20
25. Cowper PA, Udayakumar K, Sketch MH, et al. Economic effects of prolonged clopidogrel therapy after percutaneous coronary intervention. J Am Coll Cardi-ol 2005; 45 (3): 369-76
26. Kastrati A, Mehilli J, von Beckerath N, et al. Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: a randomized controlled trial. JAMA 2005; 293 (2): 165-71
27. Gold MR, Siegel JE, Russell LB, et al. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996
28. Brophy JM. The dollars and sense of drug-eluting stents. CMAJ 2005; 172 (3): 361-2
29. Cohen DJ, Cosgrove RS, Berezin RH, et al. Cost-effectiveness of gamma radiation for treatment of in-stent restenosis: results from the Gamma-1 trial. Circulation 2002; 106 (6): 691-7
30. Morice MC, Serruys PW, Sousa JE, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002; 346 (23): 1773-80
31. Lemos PA, Serruys PW, van Domburg RT, et al. Unrestricted utilization of sirolimus-eluting stents compared with conventional bare stent implantation in the "real world": the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry. Circulation 2004; 109 (2): 190-5
32. Kastrati A, Dibra A, Eberle S, et al. Sirolimus-eluting stents vs paclitaxel-eluting stents in patients with coronary artery disease: meta-analysis of randomized trials. JAMA 2005; 294 (7): 819-25
33. Cutlip DE, Chauhan MS, Baim DS, et al. Clinical restenosis after coronary stenting: perspectives from multicenter clinical trials. J Am Coll Cardiol 2002; 40 (12): 2082-9